62results about How to "Improve muscle function" patented technology

The present invention provides a device for controlling a physical therapy device adapted for accepting external commands, comprising:

• • a. a moveable portion of substantially the same shape and dimensions as that portion of said physical therapy device that is adapted for interacting with at least one part of the body of a patient;
  • b. a base;
  • c. a motion manipulation portion
  • d. conversion means for converting said stored time-dependent output signals to a series of command signals; and,
  • e. means for transmitting said command signals to said physical therapy device;

wherein a series of command signals are produced by the movement of said moveable portion, which, when transmitted to said physical therapy apparatus, will cause said physical therapy apparatus to undergo a series of motions substantially identical to those of said moveable portion.

The present invention relates to methods of increasing function and/or mass in damaged striated muscle tissue of interest (e.g., cardiac or muscle tissue) by providing of a population of multipotent adult progenitor cells (“MAPCs”), which effectively generate new striated muscle over time.

The invention relates to a propolis soft capsule. The propolis soft capsule comprises a rubber sheet and a capsule content, wherein the capsule content comprises the following components in percent by weight: 20%-60% of propolis supercritical CO2 extract, 30%-70% of wheat-germ oil and 1%-10% of vitamin E; components of the rubber sheet are gelatin, glycerol and purified water in a weight ratio of 100:42:100. The propolis soft capsule is integrated with improving effect of propolis on diabetes mellitus and preventing effect of vitamin E on chronic complication of the diabetes mellitus; moreover, the components are good in synergistic effect. The invention also provides a preparation method of the propolis soft capsule.

The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.

Nutritional products, compositions, functional ingredients, medical foods, pharmaceutical preparations and methods of use are disclosed for support and improvement of athletic performance (strength, flexibility, endurance, balance, and conditioning), and prevention and repair of injuries, including improving or maintaining muscle mitochondrial health, stimulating muscle mitochondrial biogenesis as well as other indications as set forth herein. In addition, pharmaceutical, nutraceutical and nutritional medical food compositions that are useful in conditions, normal or abnormal, associated with mitochondrial dysfunction and altered biogenesis in organ systems consisting of skeletal muscle, smooth muscle and cardiac muscle are also disclosed. L-Ergothioneine (also referred to as Ergothioneine or ET), Vitamin D2 (Ergocalciferol) and/or other antioxidants are disclosed for use in pharmaceutical, nutraceutical and nutritional medical food compositions for uses to stimulate production of bioactive molecules, including but not limited to glutathione, alpha synuclein, and IL-6.

The present disclosure relates to compositions comprising an antisense RNA sequence comprising a region of complementarity that is substantially complementary to an miRNA. Pharmaceutical compositions comprising the antisense RNA molecule, optionally further comprising an anti-inflammatory corticosteroid are also disclosed. Methods of treating or preventing inflammation, a steroid side effect, or a muscle disease using the one or the pharmaceutical compositions are also disclosed.

The present disclosure relates to a composition for alleviating, preventing or treating sarcopenia, containing, as an active ingredient, a whey protein hydrolysate, obtained by performing, on whey protein, primary hydrolysis using a Bacillus licheniformis-derived endoprotease and secondary hydrolysis using an Aspergillus oryzae-derived exoprotease, which inhibits protein degradation and activates protein synthesis through the PI3K-Akt pathway, thereby reducing muscle loss and increasing muscle size and muscle strength.

The specification discloses a method of treating muscular disorders such as muscular dystrophy comprising periodically administering an inhibitory oligonucleotide to human CD49d ((the alpha 4 chain of VLA-4).

A medical device includes an artificial contractile structure which may be advantageously used to assist the functioning of a hollow organ, an artificial contractile structure including at least one contractile element (100) adapted to contract an organ, in such way that the contractile element (100) is in a resting or in an activated position, at least one actuator designed to activate the contractile structure, and at least one source of energy for powering the actuator. The ratio “current which is needed to maintain the contractile element in its activated position and in its resting position/current which is needed to change the position of the contractile element” is less than 1/500, preferably less than 1/800, and more preferably less than 1/1000. The medical device further includes elements for reducing corrosion of the medical device.

The present invention relates to a composition for promoting mitochondrial biogenesis, which includes azelaic acid as an active ingredient. It was confirmed that azelaic acid is a compound mainly contained in cereals and natural products and has the advantage of no or little side effects, and mitochondrial autophagy and mitochondrial DNA synthesis in cells are induced, thereby ultimately having activity of increasing mitochondrial density. Therefore, azelaic acid can be used for the treatment of mitochondrial dysfunction-associated disease by the failure of homeostasis control of the mitochondria, for example, mitochondrial activity or the decrease in the number of mitochondria. In addition, azelaic acid can be provided to reinforce a muscle function and prevent muscle aging using the activity, and to be effectively used in food material, a pharmaceutical composition, and health functional foods for treating mitochondrial dysfunction-associated disease, reinforcing a muscle function, or preventing muscle aging.

A medical device including an artificial contractile structure which may be advantageously used to assist the functioning of a hollow organ. Specifically, the medical device includes an artificial contractile structure with at least one contractile element adapted to contract an organ, in such way that the contractile element is in a resting or in an activated position, at least one actuator designed to activate the contractile structure, and at least one source of energy for powering the actuator. The medical device also includes a means for reducing corrosion of the medical device hence reducing the risk of the device dysfunction and patient contamination.

A seawater mineral extract derived from seawater having a salinity of from 3.4% Brix to 3.6% Brix, wherein the seawater mineral extract comprises a mineral salt content of at least 20% of the overall seawater extract.